Trial · NCT02097264
A Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
NCT02097264, Phase 2, Withdrawn, Novo Nordisk A/S
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate. Trials, record NCT02097264. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02097264
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
- NCT number
- NCT02097264
- Status
- Withdrawn
- Phases
- Phase 2
- Enrollment
- 0 participants, actual
- Lead sponsor
- Novo Nordisk A/S
- Conditions
- Inflammation, Rheumatoid Arthritis
- Interventions
- NNC0109-0012, Adalimumab, placebo
- First posted
- 2014-03-27
- Last updated
- 2014-08-15
- Other registries' IDs
- eudract:2013-001492-20
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in the total histopathological synovitis score | Week 0, week 12 | |
| Secondary | Change in dynamic contrast enhanced MRI (DCE-MRI) measures of initial rate of enhancement (IRE) | Week 0, week 12 | |
| Secondary | Change in dynamic contrast enhanced MRI (DCE-MRI) measures of maximal enhancement (ME) | Week 0, week 12 | |
| Secondary | Changes in RA-MRI scores (RAMRIS (Rheumatoid arthritis magnetic resonance imaging)) of synovitis | Week 0, week 12 | |
| Secondary | Changes in RA-MRI scores (RAMRIS) of oedema | Week 0, week 12 | |
| Secondary | Changes in RA-MRI scores (RAMRIS) of erosion | Week 0, week 12 | |
| Secondary | Change in high frequency ultrasound with Power Doppler measures of total synovitis | Week 0, week 12 | |
| Secondary | Change in high frequency ultrasound with Power Doppler measures of total tenosynovitis scores | Week 0, week 12 | |
| Secondary | Change in disease activity 28 - C-reactive protein (DAS28 (CRP) | Week 0, week 12 | |
| Secondary | Incidence of Adverse Events (AE) | Week 0, week 24 |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02097264
GET https://conductscience.org/api/trials/v1/NCT02097264/registered